Form 4: Astera Labs Director Stefan Dyckerhoff Sells Shares

Director Stefan Dyckerhoff sold 12,499 shares of Astera Labs common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Stefan Dyckerhoff executed a series of sales of Astera Labs (ALAB) common stock on June 3, 2026.
• A total of 12,499 shares were sold at weighted average prices ranging from $364.246 to $365.087.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025.
• On June 4, 2026, the director was granted 837 restricted stock units (RSUs) which vest on the earlier of the first anniversary of the grant or the next annual stockholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine portfolio management by a director.

Positives

• The stock sales were executed under a pre-established Rule 10b5-1 plan, indicating the transactions were planned in advance rather than based on immediate non-public information.
• The director continues to maintain a significant beneficial ownership stake in the company across various trusts and limited partnerships.

Negatives

• The filing reflects a divestment of equity by a member of the board of directors.

Risks

• Future share price volatility may impact the value of the director's remaining holdings.
• The director's continued service is required for the vesting of the newly granted 837 RSUs.

Future Outlook

The filing does not provide forward-looking financial guidance for the company, focusing instead on director equity transactions.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice for executives and directors to manage personal liquidity without triggering market concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to conduct orderly divestments.
• The scale of the sale relative to the director's total holdings is consistent with typical portfolio rebalancing activities observed in the semiconductor sector.

Stakeholder Impact

• Shareholders should note the director's continued alignment with the company through significant remaining equity holdings.

Next Steps

• Vesting of 837 RSUs on the earlier of June 4, 2027, or the next annual stockholder meeting.

Key Dates

Keywords

Astera Labs, ALAB, Insider Trading, Form 4, Director Sale, Rule 10b5-1